Table 1. Investigational anti-Alzheimer’s drugs.
| Target | Drug | Study phase | Expected completion date | Results |
|---|---|---|---|---|
| β-Amyloid | CAD106 | 2 | May 2024 | |
| CNP520 | 2 | May 2024 | ||
| BAN2401 | 2 | November 2018 | ||
| LY3002813 * | 2 | December 2020 | ||
| Crenezumab | 3 | October 2022 | ||
| Aducanumab | 3 | April 2022 | ||
| UB-311 | 2 | December 2018 | ||
| Gantenerumab | 3 | November 2019 | ||
| Solanezumab | 3 | Terminated
May 2017 |
Not effective | |
| CT1812 | 2 | Completed
October 2016 |
Safe for phase 3 | |
| Thiethylperazine | 2 | July 2021 | ||
| ID1201 | 2 | December 2018 | ||
| NPT088 | 1 | February 2019 | ||
| Lu AF20513 | 1 | October 2018 | ||
| ABvac40 | 2 | February 2021 | ||
| Ponezumab | 2 | Completed
June 2011 |
Not effective | |
| ACC-001 | 2 | Completed
February 2014 |
Safe for phase 3 | |
| KHK6640 | 1 | Completed
December 2017 |
None yet | |
| GSK933776 | 2 | Completed | Not effective | |
| UB-311 | 1 | Completed | Safe for phase 2 | |
| ABvac40 | 1 | Completed
July 2015 |
Safe for phase 2 | |
| BACE1 | Lanabecestat | 2 | September 2019 | |
| JNJ-54861911 | 2 | October 2022 | ||
| Elenbecestat | 3 | December 2020 | ||
| LY3202626 * | 2 | December 2020 | ||
| Verubecestat | 3 | March 2021 | ||
| LY450139 | 3 | Completed
April 2011 |
Not effective | |
| P-tau | IONIS-MAPTRx | 1, 2 | February 2020 | |
| JNJ-63733657 | 1 | February 2019 | ||
| RO7105705 | 2 | September 2022 | ||
| ABBV-8E12 | 2 | June 2021 | ||
| AADvac1 | 2 | June 2019 | ||
| BIIB-092 | 2 | September 2020 | ||
| BIIB-080 | 1 | February 2020 | ||
| TPI-287 | 1 | Completed
May 2017 |
||
| TRx0237 | 3 | February 2019 | ||
| LY3303560 | 1 | June 2019 | ||
| APP | Posiphen | 1 | ||
| RAGE | Azeliragon | 3 | Terminated
January 2019 |
Not effective |
| Retinoid receptor | Acitretin | 2 | Completed
February 2018 |
|
| Bexarotene | 2 | Completed
February 2016 |
Potential treatments currently undergoing clinical investigation. APP, amyloid precursor protein; BACE1, β-site amyloid precursor protein cleaving enzyme 1; p-tau, hyperphosphorylated tau peptide; RAGE, receptor for advanced glycation end products.
*Medications under investigation as combination therapy. Source: www.clinicaltrials.gov.